Roche (RHHBY) receives the FDA priority review for a marketing application seeking U.S. approval of its oral multiple ...

Roche said its fenebrutinib drug candidate met primary goals in two late-stage trials for multiple sclerosis, reducing attacks or delaying disability progression in two different forms of the disease.

The FDA previously hadn’t ever accepted an application of a drug like fenebrutinib in two major forms of MS. But safety ...

The FDA agreed to speed its review of a Roche drug the developer says could be the first oral high-efficacy therapy approved ...

Quantum BioPharma Ltd. QNTM on Tuesday said it is partnering with the clinical research division of Thermo Fisher Scientific ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

ZURICH, April 22 (Reuters) - Swiss drugmaker Roche on Wednesday said it was submitting its experimental multiple ‌sclerosis drug fenebrutinib to global regulators after meeting late-stage trial goals ...

European drug regulators have given a positive review to an experimental multiple sclerosis treatment from Sanofi that the Food and Drug Administration rejected earlier this year, positioning the ...

LONDON, Sept 1 (Reuters) - (This Sept 1 story has been corrected to say that remibrutinib is approved to treat only one skin condition, not two, in paragraph 11.) Swiss drugmaker Novartis (NOVN.S), ...

Shares of Sanofi slumped on Monday as the French drugmaker said a U.S. regulatory review of its multiple-sclerosis drug won’t be completed by the end of the year and a trial for a different form of MS ...